NCI-H1975Homo sapiens (Human)Cancer cell line
Also known as: NCIH1975, H-1975, H1975
Quick Overview
Human non-small cell lung cancer cell line with EGFR mutations
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_1511 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
Age Category | Unknown |
---|---|
Sex | Female |
Disease Information
Disease | Lung adenocarcinoma |
---|---|
Lineage | Lung |
Subtype | Lung Adenocarcinoma |
OncoTree Code | LUAD |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000587_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
MutationSimple | TP53 | p.Arg273His (c.818G>A) | Homozygous | - | Unknown, PubMed=16264262 |
MutationSimple | PIK3CA | p.Gly118Asp (c.353G>A) | Heterozygous | - | from parent cell line NCI-H1975 |
MutationSimple | EGFR | p.Leu858Arg (c.2573T>G) | Unspecified | In 10% of cells | PubMed=31882684 |
MutationSimple | EGFR | p.Thr790Met (c.2369C>T) | Unspecified | Acquired during resistance selection process | PubMed=31882684 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms -- an in vitro study.
Mitsudomi T., Tsutani Y.
Biomedicines 12:1412.1-1412.13(2024).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Proteomic and ultrastructural analysis of Clara cell and type II alveolar epithelial cell-type lung cancer cells.
Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.
Transl. Cancer Res. 9:565-576(2020).
Comparative proteogenomics profiling of non-small and small lung carcinoma cell lines using mass spectrometry.
Wu J.-Y., Hao Z.-F., Ma C., Li P.-F., Dang L.-Y., Sun S.-S.
PeerJ 8:e8779.1-e8779.19(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.
Aldige C.R., Wistuba I.I., Minna J.D.
J. Cell. Biochem. 121:3986-3999(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Jimenez C.R.
J. Proteomics 196:106-119(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang Z.-H., Jiang X.-M., Guo X., Fong C.M.V., Chen X.-P., Lu J.-J.
Oncotarget 7:81598-81610(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.
Chen Y.-J.
Anal. Chem. 87:12016-12023(2015).
Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.
Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.
J. Proteome Res. 14:3658-3669(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
Lv S.
Mol. Med. Rep. 11:2767-2774(2015).
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
Wang J., Wei H., Zhao B.-X., Li M., Lv W.-P., Lv L., Song B., Lv S.
J. Mol. Histol. 45:641-652(2014).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Lack of direct association between EGFR mutations and ER beta expression in lung cancer.
Onitsuka T., Uramoto H., Tanaka F.
Anticancer Res. 31:855-860(2011).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Systems-level modeling of cancer-fibroblast interaction.";
Finn S.P., Loda M., Mahmood U., Ramaswamy S.
PLoS ONE 4:E6888-E6888(2009).
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Cell 131:1190-1203(2007).
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Takada M., Fukuoka M., Nakagawa K.
Cancer Res. 67:2046-2053(2007).